[
    [
        {
            "time": "2020-12-09",
            "original_text": "智飞生物实控人转让1.05%股份引入战略投资者，为优化股权结构减持股份。",
            "features": {
                "keywords": [
                    "智飞生物",
                    "实际控制人",
                    "大宗交易",
                    "股份转让",
                    "战略投资者"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物实控人转让1.05%股份引入战略投资者，为优化股权结构减持股份。",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-12-09",
            "original_text": "智飞生物今日大宗交易成交1680万股，成交价41.3元折价10.18%。",
            "features": {
                "keywords": [
                    "智飞生物",
                    "大宗交易",
                    "成交价",
                    "折价"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "智飞生物今日大宗交易成交1680万股，成交价41.3元折价10.18%。",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 10,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2020-12-09",
            "original_text": "A股共发生74宗大宗交易成交21.39亿元（12月9日）。",
            "features": {
                "keywords": [
                    "A股",
                    "大宗交易",
                    "成交额"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "整体市场"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "A股共发生74宗大宗交易成交21.39亿元（12月9日）。",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-12-09",
            "original_text": "智飞生物现四笔大宗交易，折价约10%成交额近7亿元。",
            "features": {
                "keywords": [
                    "智飞生物",
                    "大宗交易",
                    "折价",
                    "成交额"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "智飞生物现四笔大宗交易，折价约10%成交额近7亿元。",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 9,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-12-09",
            "original_text": "太平洋医药：智飞生物重磅产品获批在即，管线价值存预期差。",
            "features": {
                "keywords": [
                    "智飞生物",
                    "重磅产品",
                    "获批",
                    "管线价值"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "太平洋医药：智飞生物重磅产品获批在即，管线价值存预期差。",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-12-09",
            "original_text": "国盛医药张金洋团队：医药行业2020年度策略——与势偕行，因势而动——医药大变革新时代淘汰赛下的战略选择。",
            "features": {
                "keywords": [
                    "医药行业",
                    "年度策略",
                    "大变革",
                    "战略选择"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "国盛医药张金洋团队：医药行业2020年度策略——与势偕行，因势而动——医药大变革新时代淘汰赛下的战略选择。",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]